Opus Genetics, Inc. (IRD)
NASDAQ: IRD · Real-Time Price · USD
1.100
-0.010 (-0.90%)
At close: Aug 13, 2025, 4:00 PM
1.065
-0.035 (-3.17%)
Pre-market: Aug 14, 2025, 9:04 AM EDT
Opus Genetics Employees
Opus Genetics had 18 employees as of December 31, 2024. The number of employees increased by 4 or 28.57% compared to the previous year.
Employees
18
Change (1Y)
4
Growth (1Y)
28.57%
Revenue / Employee
$856,722
Profits / Employee
-$3,237,500
Market Cap
65.63M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 18 | 4 | 28.57% |
| Dec 31, 2023 | 14 | 5 | 55.56% |
| Dec 31, 2022 | 9 | 1 | 12.50% |
| Dec 31, 2021 | 8 | 3 | 60.00% |
| Dec 31, 2020 | 5 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
IRD News
- 16 hours ago - Opus Genetics Announces Financial Results for Second Quarter 2025 and Provides Corporate Update - GlobeNewsWire
- 9 days ago - Opus Genetics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference - GlobeNewsWire
- 22 days ago - Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH12 Gene Therapy for Inherited Childhood Blindness - GlobeNewsWire
- 5 weeks ago - Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia - GlobeNewsWire
- 7 weeks ago - Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program - GlobeNewsWire
- 2 months ago - Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions - GlobeNewsWire
- 3 months ago - Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update - GlobeNewsWire